Immanuel Kant Baltic Federal University is one of 10 federal universities in the Russian Federation. The university was awarded federal status on December 30, 2010. From 2010–2015, the university implemented a major expansion program valued at RUB 5 billion. In 2015, the Long-Term Development Strategy of Immanuel Kant Baltic Federal University won the International Competitiveness Award for Russian Universities.
Immanuel Kant Baltic Federal University is a leading educational institute in Russia’s westernmost region. The university currently offers over 300 secondary, higher, additional, and post-graduate professional educational programs. The university’s infrastructure includes 53 buildings. Over the past 5 years, the total area of the university area has expanded by 3.5 times. The university has its own Clinical Diagnostic Center. Over the past 5 years, our R&D funding has increased by 3.5 times.
Immanuel Kant Baltic Federal University, an innovative university in the Russian Federation, strives to maintain and further develop the academic traditions of its predecessor – Albertina Koenigsberg University. The history of Albertina, one of Europe’s oldest universities, dates back more than 460 years. Over the years, its instructors and lecturers have included: Johann Hamann, Johann Herder, Friedrich Bessel, Friedrich Jakobi, Ferdinand von Lindemann, Adolf Hurwitz, David Hilbert, and Herman von Helmholtz; the founder of Lithuanian literature Kristijonas Donelaitis studied theology at the university; and the writer and composer E.T.A. Hoffman attended lectures in philosophy. The greatest figure in the history of Koenigsberg University is undoubtedly Immanuel Kant, the great philosopher who was once a Russian citizen. His name forever tied Koenigsberg and the university with the cultural history of all mankind and became a landmark of the region.
The university sees its mission as developing a leading national university in new areas and activities based on breakthroughs in biomedicine and neuro- and nano-technologies, setting industry standards, and producing highly qualified professionals who are competitive on the global market. Our priority is R&D in biomedicine and neurotechnologies, which deliver products and services aimed at extending a high-quality life.